CTOs on the Move

Onyx Pharmaceuticals

www.onyx.com

 
At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve.   By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.onyx.com
  • 249 E. Grand Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.266.0000

Executives

Name Title Contact Details

Similar Companies

Spokane Inter Res Tech Ins

Spokane Inter Res Tech Ins is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GTC Biotherapeutics, Inc.

GTC Biotherapeutics, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

TubeWriter

TubeWriter is a company that provides direct labeling systems and services to the life sciences industry. Their solutions print on any laboratory tube, slide or plate, and offer superior durability of print at extreme temperatures, up to 90% reduction ...

Syros

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.